Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone). PIXUVRI is the first medicinal product approved in the European Union (E.U.) for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.
"We are pleased to have reached an agreement with the GKV-SV on the reimbursement price of PIXUVRI so that hematologists in Germany may continue to treat patients with the only approved treatment for this aggressive disease," said James A. Bianco, M.D., President and Chief Executive Officer of CTI. "PIXUVRI is the first medicinal product approved in the E.U. for the treatment of patients with aggressive non-Hodgkin B-cell lymphoma who have failed two or three prior lines of therapy, which was based on results from the only Phase 3 trial conducted in this patient population. Given the response rates seen in this trial, PIXUVRI may provide an effective salvage or palliative treatment option for this patient population where there are no other approved agents. The conclusion of these pricing negotiations brings welcome clarity and confidence to German physicians regarding the reimbursement status of PIXUVRI."
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics